For the first time in a multicenter phase 3 trial, an overall survival (OS) benefit was provided by one therapy over another in platinum-resistant ovarian cancer. The findings were reported in a late-breaking presentation at the 2023 annual meeting of the American Society of Clinical Oncology (abstract LBA5507).
Although OS was a secondary outcome in the phase 3 trial, called MIRASOL, the greater degree of activity, along with a meaningful improvement on the primary outcome of progression-free